PMHNP-BC review, planned by domain weight

1. Baseline. Before opening a book, do the practice test and note which domains cost you points.
2. Assessment and risk (27%). Mental status vocabulary, screening tool cut-offs, suicide and violence risk, withdrawal scales: advanced practice skills.
3. Drugs, studied once across two domains. Take each class in turn (antidepressants, antipsychotics, mood stabilizers, anxiolytics and hypnotics, stimulants, addiction medicines). Learn the mechanism and kinetics for the scientific foundation, then choice, dosing and monitoring by age for diagnosis and treatment.
4. DSM-5-TR diagnoses, with duration thresholds and differentials; rule out medical and substance causes first.
5. Ethics and law (17%). Learn principles that hold in every state: ethics, legal and cultural care.
6. Psychotherapy (11%). Match therapy to disorder rather than memorizing theorists: psychotherapy and related theories. Finish with the practice set again, timed.

Short daily sessions on blocks 5 and 6 work better than leaving them to the last week; together they hold 28% of the scored items.

• The outline itself. The current domains come from the outline (Apr 28, 2023). A resource built on an earlier outline may group content differently and give different weights.
• DSM-5-TR (2022). Prolonged grief disorder became a diagnosis, and codes were added for suicidal behavior and nonsuicidal self-injury.
• Clozapine. FDA ended the clozapine REMS program in 2025, so pharmacies no longer check a REMS registry before dispensing. Neutrophil monitoring is still in the drug’s labeling (FDA).
• Buprenorphine. The Consolidated Appropriations Act, 2023 removed the separate DATA (“X”) waiver; a DEA registration that covers Schedule III is enough to prescribe it for opioid use disorder.
• New drugs. FDA approved zuranolone, an oral treatment for postpartum depression, in 2023 and xanomeline-trospium, a muscarinic drug for schizophrenia, in 2024. Older books have neither.
• SUD records. HHS revised the 42 CFR Part 2 confidentiality rule in 2024 to align it more closely with HIPAA, with compliance due by February 16, 2026.

The exam page lists these study aids (exam page, Study Aids):

• the test content outline, the only official statement of what is tested;
• the test reference list, the texts item writers draw on;
• a readiness test for this specialty and a page of sample questions;
• the role delineation study behind the outline, and a short tips sheet.

ANCC adds that using these or any course does not imply eligibility or a pass, and that it endorses no products.

Candidates search for courses by name (Fitzgerald, Barkley, Georgette and others) and for the Psychiatric-Mental Health Nurse Practitioner Review and Resource Manual. We don’t rank them. Four checks before paying:

1. Does it state which outline it follows, and is that the April 2023 one?
2. Does it cover children, adolescents and frail older adults, or only adult psychiatry?
3. Is its drug content current on the changes above?
4. Do its practice items explain every option, or only the key?

A large psychopharmacology textbook is a reference, not a review plan; use it to look up what your practice misses point to.